Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

z-Movi cell screening and sorting platform

Project description

A novel platform for immunotherapy research and development

Despite its potential, immunotherapy against cancer has been met with limited clinical success. Therefore, there is a pressing need for alternative strategies to awaken the immune system against cancer customised for individual patients or according to tumour type. Towards this goal, scientists of the EU-funded LUMICKS project are developing z-Movi, the first high-throughput platform with a capacity to screen and sort immune cells based on their functionality. z-Movi will expedite the process of bringing new immunotherapy treatments to the market, therefore becoming an invaluable tool in the biopharmaceutical research and development pipeline.

Objective

Cell immunotherapy is a breakthrough treatment that uses immune cells to directly attack tumours. It is considered the most
exciting development in cancer treatment in years. When it works, patients with life-threatening cancers live far longer or
may even be cured. But so far, immunotherapy only works for few types of cancer and few patients, and finding the most
effective immune cells is still an immense challenge.
LUMICKS is developing z-Movi, the first high-throughput platform that screens and sorts immune cells based on their
functionality using non-invasive techniques. z-Movi is a unique and powerful solution that now allows researchers to look at
thousands of immune cells and find the right ones within a couple of minutes – a process that would take months with
standard technologies. Therefore, z-Movi is the perfect R&D tool to help and speed up the process of bringing new
immunotherapy treatments to market. z-Movi is expected to disrupt the immunotherapy market, which is mostly driven by
innovation and is expected to reach €100B by 2021.
LUMICKS started by teaming-up with immunotherapy leaders such as the Dutch Cancer Institute and Institut Pasteur to
develop z-Movi. The first developed z-Movi was already introduced to early adopters. After completing optimisation, a new
generation z-Movi will target the immunology research institutes, biotech and pharma markets. Users from those segments
have already demonstrated concrete interest in our solution, or are in the process of acquisition. The incremental z-Movi
revenue stream from this EIC Accelerator project will be around €20M by 2022 and the net profit margin will double.
LUMICKS’ post-EIC ultimate goal is to go beyond the

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

LUMICKS CA BV
Net EU contribution
€ 1 284 500,00
Address
PAALBERGWEG 3
1105 AG Amsterdam
Netherlands
SME
Yes
Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 1 835 000,00

Participants (1)